Wegovy (Semaglutide) vs. Mounjaro (Tirzepatide): A Patient's Guide
Wegovy and Mounjaro are both injectable medications used to help manage health conditions, but they work in slightly different ways. Patients often compare these drugs because they are both effective for weight management and have similar administration methods, though their primary approved uses differ.
Side-by-Side Comparison
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Drug Class | GLP-1 Receptor Agonist | GIP and GLP-1 Receptor Agonist (Dual Agonist) |
| Primary Approved Use | Weight loss (adults and children 12+), Cardiovascular risk reduction in adults with established CV disease | Glycemic control in adults and pediatric patients 10+ with type 2 diabetes |
| Mechanism of Action | Mimics GLP-1 hormone, activating GLP-1 receptors | Mimics both GIP and GLP-1 hormones, activating both GIP and GLP-1 receptors |
| Key Advantage | Specifically approved for weight loss, proven cardiovascular benefits | Dual action may lead to greater blood sugar control and weight loss in type 2 diabetes |
| Main Limitation | Not specifically approved for type 2 diabetes glycemic control (though it lowers blood sugar) | Not specifically approved for weight loss in non-diabetics (though it causes weight loss) |
| Warnings | Acute Pancreatitis, Acute Gallbladder Disease | Acute Pancreatitis, Hypoglycemia (with concomitant insulin/sulfonylurea) |
| When to Choose | A doctor might prefer Wegovy if the primary goal is weight loss for an adult or child aged 12 and older, especially if the patient also has established cardiovascular disease and needs to reduce their risk of major adverse cardiovascular events. It's a strong choice when weight management is the main focus. | A doctor might prefer Mounjaro if the patient has type 2 diabetes and the primary goal is to improve blood sugar control. Its dual action on GIP and GLP-1 receptors can lead to very effective glycemic management, often with significant weight loss as an additional benefit. |
| Side Effects | Both medications share common gastrointestinal side effects like nausea, vomiting, diarrhea, and constipation, as well as a risk of pancreatitis. Mounjaro carries an additional warning for hypoglycemia when used with insulin or sulfonylureas, while Wegovy has a specific warning for acute gallbladder disease. | |
| Cost | Neither Semaglutide (Wegovy) nor Tirzepatide (Mounjaro) are available as generics; both are brand-name medications. They are generally considered high-cost drugs, and insurance coverage can vary significantly. |
Bottom Line
Wegovy and Mounjaro are powerful injectable medications that can significantly improve health outcomes, but their primary approved indications differ. Your doctor will consider your specific health conditions, such as the presence of type 2 diabetes, cardiovascular disease, or the primary need for weight loss, to determine which medication is most appropriate for you.
Semaglutide Overview
Semaglutide is a once-weekly (or once-daily oral) GLP-1 receptor agonist that lowers blood sugar and reduces body weight by mimicking the natural gut hormone GLP-1. It is sold under three brand names — Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral tablet, type 2 diabetes) — all manufactured by Novo Nordisk. Clinical trials show it reduces HbA1c by up to 2.0 percentage points and body weight by up to 15% at the highest injectable dose.
Full Semaglutide guide →Tirzepatide Overview
Tirzepatide is a once-weekly injectable prescription medication that activates both the GIP and GLP-1 hormone receptors — making it the first dual GIP/GLP-1 receptor agonist approved by the FDA. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. Clinical trials show it reduces HbA1c by up to 2.58 percentage points and body weight by up to 20.9% at the highest dose.
Full Tirzepatide guide →Compare prices for Semaglutide and Tirzepatide
Check real-time pharmacy prices before you fill — free, no account needed.
Protect your muscle mass on GLP-1 medications
GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.
No credit card. No commitment.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.